Trial · NCT01099774
Adverse events16
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 16 of 16
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Conjunctival Hyperaemia | Eye disorders | Bimatoprost 0.03% Formulation B Ophthalmic Solution | 72 | 301 | |
| other | Conjunctival Hyperaemia | Eye disorders | Bimatoprost 0.03% Ophthalmic Solution | 77 | 295 | |
| serious | Ovarian Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bimatoprost 0.03% Formulation B Ophthalmic Solution | 1 | 301 | |
| serious | Ovarian Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bimatoprost 0.03% Ophthalmic Solution | 0 | 295 | |
| serious | Spinal Compression Fracture | Injury, poisoning and procedural complications | Bimatoprost 0.03% Formulation B Ophthalmic Solution | 1 | 301 | |
| serious | Spinal Compression Fracture | Injury, poisoning and procedural complications | Bimatoprost 0.03% Ophthalmic Solution | 0 | 295 | |
| serious | Atrial Fibrillation | Cardiac disorders | Bimatoprost 0.03% Formulation B Ophthalmic Solution | 0 | 301 | |
| serious | Atrial Fibrillation | Cardiac disorders | Bimatoprost 0.03% Ophthalmic Solution | 1 | 295 | |
| serious | Convulsion | Nervous system disorders | Bimatoprost 0.03% Formulation B Ophthalmic Solution | 0 | 301 | |
| serious | Convulsion | Nervous system disorders | Bimatoprost 0.03% Ophthalmic Solution | 1 | 295 | |
| serious | Death | General disorders | Bimatoprost 0.03% Formulation B Ophthalmic Solution | 0 | 301 | |
| serious | Death | General disorders | Bimatoprost 0.03% Ophthalmic Solution | 1 | 295 | |
| serious | Syncope | Nervous system disorders | Bimatoprost 0.03% Formulation B Ophthalmic Solution | 0 | 301 | |
| serious | Syncope | Nervous system disorders | Bimatoprost 0.03% Ophthalmic Solution | 1 | 295 | |
| serious | Transitional Cell Carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bimatoprost 0.03% Formulation B Ophthalmic Solution | 0 | 301 | |
| serious | Transitional Cell Carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bimatoprost 0.03% Ophthalmic Solution | 1 | 295 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01099774/events